" class="no-js "lang="en-US"> Astellas Pharma Archives - Medtech Alert
Saturday, September 30, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Read more

News

 FDA Grants Accelerated Approval for PADCEV® with KEYTRUDA for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer | MTA

FDA Grants Accelerated Approval for PADCEV® with KEYTRUDA for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer

Seagen and Astellas Pharma have announced the United States Food and Drug Administration (FDA) has […]

News

 MIMETAS and Astellas Enter into Strategic Partnership | MTA

MIMETAS and Astellas Enter into Strategic Partnership

MIMETAS, a global leader in human disease modeling, announces that it has entered into a […]

Diseases

 Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer | MTA

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Pfizer and Astellas Pharma have announced positive topline results from the Phase 3 EMBARK trial […]

Clinical Trials

 Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib | MTA

Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib

Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) today announced […]

Drug Development

 Astellas Provides Update on Fezolinetant New Drug Application in U.S. | MTA

Astellas Provides Update on Fezolinetant New Drug Application in U.S.

Astellas Pharma has announced the US Food and Drug Administration (FDA) notified the company that […]

Diseases

 Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology | Pharmtech Focus

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and GO Therapeutics, Inc. (Co-Founder […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more